Katharina Meier

Katharina Meier

Auto-generated profile, based on publicly available information

Katharina Meier

Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
FSFarzan Solimani
Farzan Solimani
YMYasmine Mansour
Yasmine Mansour
DDDario Didona
Dario Didona
ADAmrei Dilling
Amrei Dilling
KGKamran Ghoreschi
Kamran Ghoreschi
KMKatharina Meier
Katharina Meier
Pemphigus vulgaris (PV) is a rare and severe autoimmune disorder of skin and mucosa. In PV, the production of autoantibodies against desmosomal proteins of the skin, namely desmoglein (Dsg) 1 and Dsg3 leads to a clinical phenotype characterized by blistering and severe erosions. Several factors including genetic susceptibility, certain drugs, and malignant disorders have been reported to trigger or exacerbate PV1. Here, we report the first case of a patient, who developed PV following COVID-19 vaccination with the mRNA vaccine BNT162b2 (Comirnaty®, Biontech/Pfizer).

27 October 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
KMKatharina Meier
Katharina Meier
JHJulia Holstein
Julia Holstein
FSFarzan Solimani
Farzan Solimani
JWJens Waschke
Jens Waschke
KGKamran Ghoreschi
Kamran Ghoreschi
Background: In pemphigus, elucidating the disease-causing immune mechanism and developing new therapeutic strategies are needed. In this context, the second messenger 3′,5′-cyclic adenosine monophosphate (cAMP) is gaining attention. cAMP is important in hematological and auto-inflammatory disorders. A class of enzymes called phosphodiesterases (PDEs) control intracellular cAMP levels. In pemphigus, cAMP levels increase following IgG binding to Dsg3. This appears to be a mechanism to preserve epithelial integrity. Objectives: To determine whether apremilast, an inhibitor of the PDE4 normally used in psoriasis, may be of benefit in the blistering skin disorder pemphigus. Methods: Here we report of a 62 years old patient with chronic debilitating and recalcitrant pemphigus not responding to several previous treatments, who received treatment with apremilast over a period of 32 weeks. Desmoglein autoantibody levels were assessed by Enzyme-linked Immunosorbent Assay (ELISA), whereas disease severity and quality of life were assessed by the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). In an attempt to explain the effects of apremilast in pemphigus, peripheral blood mononuclear cells (PBMCs) were analyzed for the duration of treatment by flow cytometry for the distribution of specialized T cell subsets. The frequencies of circulating T helper (Th) 1, Th2, Th17, Th17.1 and T follicular helper (Tfh) 1, Tfh2, Tfh17, and Tfh17.1 were analyzed by CCR6, CXCR3, and CXCR5 expression of CD4+ T cells. Further, based on the different expressions of CXCR5, CD127, and CD25, we analyzed the T regulatory (Treg) and T follicular regulatory (Tfreg) compartment. Results: In response to apremilast treatment, Dsg-specific autoantibody titers decreased, blistering ceased and lesions healed, showing a long-lasting effect. While the frequencies of most of the Th and Tfh cell subsets remained unchanged, we observed a continuous increase in Treg and Tfreg cell levels. Conclusion: Our findings are encouraging and warrant extension of the beneficial effect of PDE4 inhibition on a larger cohort of pemphigus patients.

1 January 2020 in Therapeutic Advances in Musculoskeletal Disease
Verified
Journal Article
Open access
PDF file
KMKatharina Meier
Katharina Meier
ASAlexandra Schloegl
Alexandra Schloegl
DPDenis Poddubnyy
Denis Poddubnyy
KGKamran Ghoreschi
Kamran Ghoreschi
Spondyloarthritides (SpA) like psoriatic arthritis, axial spondyloarthritis/ankylosing spondylitis, reactive arthritis and inflammatory bowel disease (IBD)-associated SpA can present with characteristic skin manifestations. These SpA-associated skin disorders may precede joint involvement, reflect a loss of efficacy of a current systemic treatment or can even be treatment associated. Cutaneous manifestations in SpA not only add additional morbidity with physical impact but also impose a psychosocial burden on affected patients. Psoriasis (PsO) – the main skin disease in SpA – has a variety of clinical presentations, including plaque-type PsO, inverse PsO, guttate PsO, erythrodermic PsO, nail PsO and pustular types. SpA associated with IBD presents with neutrophilic and granulomatous skin disorders, including pyoderma gangrenosum, hidradenitis suppurativa and cutaneous Crohn’s disease. Reactive arthritides has a favourable prognosis and may feature keratoderma blenorrhagicum or balanitis circinatum as typical skin manifestations. Immunologically, SpA-associated skin diseases share interleukin (IL)-17 and IL-23 dysregulation but show distinctive genetic and immunological profiles. Therefore, they vary in their treatment responses to targeted therapies with biologicals or small molecules. In this review, we highlight the clinical presentation of skin manifestations in SpA and discuss therapeutic approaches in this interdisciplinary field.

7 April 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
FSFarzan Solimani
Farzan Solimani
AMAlberto Mesas‐Fernández
Alberto Mesas‐Fernández
ADAmrei Dilling
Amrei Dilling
ANAlexander Nast
Alexander Nast
FHFranz J. Hilke
Franz J. Hilke
KMKatharina Meier
Katharina Meier

26 November 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
FSFarzan Solimani
Farzan Solimani
ADAmrei Dilling
Amrei Dilling
FGFranziska C. Ghoreschi
Franziska C. Ghoreschi
ANAlexander Nast
Alexander Nast
KGKamran Ghoreschi
Kamran Ghoreschi
KMKatharina Meier
Katharina Meier

17 November 2021 in Mycoses
Verified
Journal Article
Open access
PDF file
KEKevin Elsner
Kevin Elsner
JHJulia Holstein
Julia Holstein
FHFranz Joachim Hilke
Franz Joachim Hilke
GBGunnar Blumenstock
Gunnar Blumenstock
BWBirgit Walker
Birgit Walker
KMKatharina Meier
Katharina Meier
Background: Psoriasis patients are more frequently colonised with Candida species. The correlation between fungal colonisation and clinical severity is unclear, but may exacerbate psoriasis and the impact of antipsoriatic therapies on the prevalence of Candida is unknown.Objectives: To examine the prevalence of C species in psoriasis patients compared to an age‐ and sex‐matched control population, we investigated the influence of Candida colonisation on disease severity, immune cell activation and the interplay on psoriatic treatments.Methods: The prevalence of C species was examined in 265 psoriasis patients and 200 control subjects by swabs and stool samples for fungal cultures. Peripheral mononuclear blood cells (PBMCs) were collected from 20 fungal colonised and 24 uncolonised patients and stimulated. The expression of interferon (IFN)‐γ, IL‐17A, IL‐22 and tumour necrosis factor (TNF)‐α from stimulated PBMCs was measured by quantitative real‐time polymerase chain reaction (qPCR).Results: A significantly higher prevalence for Candida was detected in psoriatic patients (p ≤ .001) compared to the control subjects; most abundant in stool samples, showing Candida albicans. Older participants (≥51 years) were more frequent colonised, and no correlation with gender, disease severity or systemic treatments like IL‐17 inhibitors was found.Conclusions: Although Candida colonisation is significantly more common in patients with psoriasis, it does not influence the psoriatic disease or cytokine response. Our study showed that Candida colonisation is particularly more frequent in patients with psoriasis ≥51 years of age. Therefore, especially this group should be screened for symptoms of candidiasis during treatment with IL‐17 inhibitors.